EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population

Louise A Donnelly iD, Katyayeni Singh iD, Rory J McCrimmon iD, Ewan R Pearson iD

Diabetes, Obesity and Metabolism · 2026-02 · 28 (2) · 972-981

DOI: 10.1111/dom.70269 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 04.11.2025. Verfasst von Louise A Donnelly und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Endocrinology and Reproductive Biology, School of Medicine, University of Dundee, Dundee, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative 2 Joint Undertaking.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Real‐world studies of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage. We describe patterns across individual subclasses, and in overall class‐level models, we examined clinical characteristics associated with each category with particular interest in poor adherence and intolerance. Materials and Methods We conducted an observational cohort study using electronic health records from the Scottish Care Information Diabetes Collaboration database, including individuals with type 2 diabetes who initiated a SGLT2i or GLP‐1RA. Each initiation was followed for 1 year and classified into five mutually exclusive groups: adherent, poor adherence and three discontinuation categories including a proxy for intolerance.

Results

Among SGLT2is, poor adherence was more common in younger individuals, with greater socioeconomic deprivation, and higher HbA 1c , while intolerance was more frequent in older, leaner females and in those with prior genital thrush. For GLP‐1RAs, newer agents were associated with more favourable usage patterns. Poor adherence was more frequent with liraglutide, lixisenatide, and exenatide compared to semaglutide, and intolerance was more common with lixisenatide. In addition, poor adherence was associated with younger age and prior GLP‐1RA use, while intolerance was linked to lower BMI, female sex, and more advanced CKD.

Conclusions

Distinct clinical and biochemical characteristics are associated with poor adherence versus discontinuation. Understanding these patterns is crucial for developing targeted strategies to improve sustained use, ultimately enhancing treatment outcomes for people with type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsHumansFemaleMaleMiddle AgedAgedScotlandGlycated HemoglobinCohort StudiesMedication Adherence

Stichwörter der Autor:innen

GLP‐1 analogueSGLT2 inhibitorcohort studydatabase researchreal‐world evidencetype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlycated Hemoglobin

Autor:innen und Institutionen

  • Diabetes Endocrinology and Reproductive Biology, School of Medicine, University of Dundee, Dundee, UK.

ORCID-Profile: Louise A Donnelly, Katyayeni Singh, Rory J McCrimmon, Ewan R Pearson

Förderung

  • Innovative Medicines Initiative 2 Joint Undertaking

Zitieren

APA

Donnelly, L. A., Singh, K., McCrimmon, R. J., & Pearson, E. R. (2026). One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population. Diabetes, Obesity and Metabolism, 28(2), 972-981. https://doi.org/10.1111/dom.70269

Vancouver

Donnelly LA, Singh K, McCrimmon RJ, Pearson ER. One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population. Diabetes, Obesity and Metabolism. 2026;28(2):972-981. doi:10.1111/dom.70269

BibTeX
@article{Donnelly2026,
  author = {Donnelly, Louise A and Singh, Katyayeni and McCrimmon, Rory J and Pearson, Ewan R},
  title = {One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {2},
  pages = {972--981},
  doi = {10.1111/dom.70269}
}
Kostenlos starten →